These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37545470)

  • 41. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials.
    Carvalho PEP; Veiga TMA; Simões E Silva AC; Gewehr DM; Dagostin CS; Fernandes A; Nasi G; Cardoso R
    Clin Res Cardiol; 2023 Aug; 112(8):1044-1055. PubMed ID: 36592186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan.
    Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Hsiao KY; Wu MJ; Shieh JJ; Huang YC; Chung CJ
    JAMA Netw Open; 2023 Feb; 6(2):e230453. PubMed ID: 36811856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study).
    Patil T; Halsey E; Kaur A; Minchak J; Hobson J; Eppes D
    Clin Drug Investig; 2023 Jan; 43(1):61-74. PubMed ID: 36515856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat.
    Girerd N; Zannad F
    J Intern Med; 2023 May; 293(5):550-558. PubMed ID: 36871279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
    Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Chatur S; Vaduganathan M; Claggett B; Vardeny O; Desai AS; Jhund PS; de Boer RA; Lam CSP; Kosiborod MN; Shah SJ; Martinez F; Inzucchi SE; Hernandez AF; Haddad T; Mitter SS; Miao ZM; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
    Eur Heart J; 2023 Aug; 44(31):2930-2943. PubMed ID: 37220093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
    Butler J; Usman MS; Filippatos G; Ferreira JP; Böhm M; Brueckmann M; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Senni M; Sumin M; Verma S; Zaremba-Pechmann L; Pocock SJ; Packer M; Anker S
    JAMA Cardiol; 2023 Jul; 8(7):640-649. PubMed ID: 37223933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
    Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
    Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
    Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction.
    Chang HY; Su YW; Feng AN; Fong MC; Huang KC; Chong E; Chen KC; Yin WH
    ESC Heart Fail; 2020 Apr; 7(2):604-615. PubMed ID: 31995274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors.
    Perlman A; Heyman SN; Stokar J; Darmon D; Muszkat M; Szalat A
    Isr Med Assoc J; 2018 Aug; 20(8):513-516. PubMed ID: 30084579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan.
    Adie SK; Ketcham SW; Abdul-Aziz AA; Thomas MP; Konerman MC
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):403-406. PubMed ID: 34173810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
    Johansen ME; Argyropoulos C
    Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration.
    George J; Lobkovich A; Nardolillo J; Farhat N; Kolander S; Thomas E
    Am J Health Syst Pharm; 2022 Jul; 79(14):1151-1157. PubMed ID: 35136945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.